Experimental for Liver Cancer

Phase 1 & 2

Waitlist Available

Led By Nabeel Badri

Research Sponsored by University of Rochester

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 10 years

Awards & highlights

Study Summary

This trialtests a new combination therapy for unresectable or metastatic liver cancer to see if it's safe and effective.

Eligible Conditions

Liver Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 10 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~10 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 10 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

Trial Design

1Treatment groups

Experimental Treatment

Group I: ExperimentalExperimental Treatment1 Intervention

Open label safety and tolerability assessment of PXS-5505: (PXS-5505) 100-200mg BID (Atezolizumab) 1200mg every 3 weeks (Bevacizumab) 15mg/kg every 3 weeks

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of RochesterLead Sponsor

845 Previous Clinical Trials

535,017 Total Patients Enrolled

Nabeel BadriPrincipal InvestigatorUniv. of Rochester Wilmot Cancer Center

1 Previous Clinical Trials

25 Total Patients Enrolled

~0 spots leftby Dec 2028

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.